Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion
08. Dezember 2020 16:05 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced the completion of the previously announced transaction whereby Novo...
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion
06. November 2020 08:00 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S...
EMISPHERE DEVELOPMENT UPDATE
06. April 2020 08:30 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Novo Nordisk announced the European Commission (EC) has granted marketing authorization for Rybelsus®, (oral semaglutide), for the treatment of...
Emisphere Development Update
20. September 2019 12:31 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the Federal Food and Drug Administration (FDA) has approved Rybelsus, a semaglutide tablet, for the treatment of...
Emisphere Announces Leadership Changes
10. September 2019 08:30 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCMKTS: EMIS) today announced that Alan L. Rubino, will retire as President and Chief Executive Officer (CEO)...
Emisphere Development Update
26. April 2019 10:29 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., April 26, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for oral...
Emisphere Development Update
20. März 2019 13:58 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk announced today it has submitted two New Drug Applications (“NDA”) to the US Food and Drug Administration (“FDA”) for oral...
Emisphere Development Update
26. November 2018 09:36 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a...
Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide
28. August 2018 16:05 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- On August 20, 2018, Novo Nordisk A/S (Novo Nordisk) announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults...
Emisphere Development Update
29. Juni 2018 08:30 ET
|
Emisphere Technologies, Inc.
ROSELAND, N.J., June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation...